

## LUTS pharmacotherapy: Any news?

Poster Session 69

Monday, 14 March  
12:15 - 13:45

**Location:** Room 14a (ICM, Level 1)

**Chairs:** A. Ergen, Ankara (TR)  
R. Umbas, Jakarta (ID)  
A. Sahai, London (GB)

### Aims and objectives of this presentation

Basic and clinical news from the wide field of LUTS pharmacotherapy will be covered during this session

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 867 **Long term efficacy of a combination therapy with an anticholinergic agent and an  $\alpha$  1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective, comparative trial using a urodynamic study**  
By: [Matsukawa Y.](#), Takai S., Fujita T., Majima T., Kato M., Yamamoto T., Gotoh M.  
**Institutes:** Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan
- 868 **Dutasteride in combination with imidafenacin versus dutasteride alone for management of benign prostatic enlargement with overactive bladder: A multicenter, randomized controlled trial**  
By: [Yamanishi T.](#)<sup>1</sup>, Asakura H.<sup>2</sup>, Seki N.<sup>3</sup>, Tokunaga S.<sup>4</sup>  
**Institutes:**<sup>1</sup>Dokkyo Medical University, Dept. of Urology, Continence Center, Tochigi, Japan, <sup>2</sup>Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, <sup>3</sup>Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, <sup>4</sup>Kyushu University Hospital, Medical Information Center, Fukuoka, Japan
- 869 **Effects of withdrawing the alpha-1 blocker from alpha-1 blocker plus 5-alpha-reductase inhibitor combination therapy on patients with benign prostatic hyperplasia from the perspective of urodynamic study**  
By: Matsukawa Y., Funahashi Y., Matsuo K., [Ishida S.](#), Yoshino Y., Yamamoto T., Gotoh M.  
**Institutes:** Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan
- 871 **Surgical outcome of BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study**  
By: [Huang E.Y.-H.](#), Chung H.J., Lin C.-C., Fan Y.H., Peng R.S., Chang Y.H., Lin A.T.L., Chen K.K.  
**Institutes:** Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- 872 **Cardiovascular (CV) assessments in a randomized, double-blind, phase 3b trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to solifenacin monotherapy**  
By: [Drake M.J.](#)<sup>1</sup>, Chapple C.<sup>2</sup>, Esen A.A.<sup>3</sup>, Athanasiou S.<sup>4</sup>, Cambronero J.<sup>5</sup>, Mitcheson D.<sup>6</sup>, Herschorn S.<sup>7</sup>, Huang M.<sup>8</sup>, Siddiqui E.<sup>8</sup>, Stozel M.<sup>9</sup>, Herholdt C.<sup>8</sup>, Mac Diarmid S.<sup>10</sup>  
**Institutes:**<sup>1</sup>University of Bristol, Bristol Urological Institute, Bristol, United Kingdom, <sup>2</sup>Royal Hallamshire Hospital, Sheffield Hallam University, Sheffield, United Kingdom, <sup>3</sup>Dokuz Eylül University School of Medicine, Dept. of Urology, Izmir, Turkey, <sup>4</sup>University of Athens Medical School, Dept. of Urology, Athens, Greece, <sup>5</sup>Hospital Universitario Infanta Leonor, Madrid, Spain, <sup>6</sup>St Elizabeths Medical Center, Brighton, Massachusetts, United States of America, <sup>7</sup>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, <sup>8</sup>Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom, <sup>9</sup>Astellas Pharma Global Development, Leiden, The Netherlands, <sup>10</sup>Alliance Urology Specialists, Greensboro, North Carolina, United States of America

- 873 **Tadalafil improves storage dysfunction via increase in bladder blood flow and suppression of ATP release from the urothelium in metabolic syndrome rats**  
 By: Zha X., Ito H., Aoki Y., Matsuta Y., Yamaguchi H., Yokoyama O.  
 Institutes: Faculty of Medical Science, University Of Fukui, Dept. of Urology, Yoshida-gun, Japan
- 874 **Alpha1-adrenoceptor antagonist ameliorates memory impairment in the patient with LUTS? A study about the influence of tamsulosin on the memory impairment through enhancement of alpha1A-adrenoceptor in the hippocampus of old-aged rats**  
 By: Kim S.<sup>1</sup>, Kim CH<sup>2</sup>, Cho Y.S.<sup>3</sup>, Yoon S.J.<sup>2</sup>, Kim K.T.<sup>2</sup>, Kim T.B.<sup>2</sup>, Kim K.H.<sup>2</sup>  
 Institutes:<sup>1</sup>The Catholic University of Korea, Kangnam St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, <sup>2</sup>Gachon University Gil Medical Center, Gachon University School of Medicine, Dept. of Urology, Incheon, South Korea, <sup>3</sup>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea
- 875 **Evaluation of tamsulosin therapy in the treatment of indwelling double-J stent related discomfort**  
 By: Moussa A., Mohammed H., Abd-Bary A., Gaber A., El-Dessouky A., Masoud, A.  
 Institutes: Beni Suef University, Dept. of Urology, Beni Suef, Egypt
- 876 **Role of silodosin in decreasing lower urinary tract and sexual problems in male patients with double J ureteral stents**  
 By: Hussein H.A.<sup>1</sup>, Shaker H.<sup>2</sup>, Fathy H.<sup>1</sup>, Sheeba M.<sup>1</sup>, Abdelazim M.S.<sup>1</sup>, Bedair A.S.<sup>1</sup>, Aly A.H.<sup>1</sup>  
 Institutes:<sup>1</sup>Cairo University, Dept. of Urology, Cairo, Egypt, <sup>2</sup>Fayoum University, Dept. of Urology, Fayoum, Egypt
- 877 **The efficacy and safety of onabotulinumtoxinA and solifenacin compared to placebo in solifenacin-naïve patients with idiopathic overactive bladder: Results from a multicentre, randomised, double-blind, phase 3b trial**  
 By: Everaert K.<sup>1</sup>, Sriram R.<sup>2</sup>, Kohan A.<sup>3</sup>, Aliotta P.<sup>4</sup>, Mc Cammon K.<sup>5</sup>, Abrams S.<sup>6</sup>, Lam W.<sup>7</sup>, Herschorn S.<sup>8</sup>  
 Institutes:<sup>1</sup>Ghent University Hospital, Dept. of Urology, Ghent, Belgium, <sup>2</sup>University Hospital Coventry, Dept. of Urology, Coventry, United Kingdom, <sup>3</sup>Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America, <sup>4</sup>Western New York Urology Associates, Dept. of Urology, Williamsville, United States of America, <sup>5</sup>Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, <sup>6</sup>Allergan Plc, Dept. of Urology, Irvine, United States of America, <sup>7</sup>Allergan Plc, Dept. of Biostatistics, Irvine, United States of America, <sup>8</sup>University of Toronto, Dept. of Urology, Toronto, Canada
- 878 **Licensed and approved vs traditional dose of onabotulinumtoxinA in refractory overactive bladder?**  
 By: Eldred-Evans D.<sup>1</sup>, Seth J.<sup>1</sup>, Dowson C.<sup>2</sup>, Malde S.<sup>3</sup>, Watkins J.<sup>1</sup>, Khan M.S.<sup>1</sup>, Dasgupta P.<sup>1</sup>, Sahai A.<sup>1</sup>  
 Institutes:<sup>1</sup>Guy's and St Thomas' Nhs Trust, Pelvic floor unit, London, United Kingdom, <sup>2</sup>Guy's and St Thomas' Nhs Trust, Dept. of Urology, London, United Kingdom, <sup>3</sup>University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- 879 **Preoperative serum C-reactive protein in patients with pelvic organ prolapse is a predictor of de novo overactive bladder**  
 By: Tomohiro M., Ohba K., Yasuda T., Asai A., Miyata Y., Sakai H.  
 Institutes: Nagasaki University School of Medicine, Dept. of Urology, Nagasaki, Japan
- 13:30 - 13:37 **Summary and context**  
 A. Sahai, London (GB)